Biocryst Pharmaceuticals buy Jefferies Financial Group Inc.
Start price
04.08.23
/
50%
€6.90
Target price
04.08.24
-
Performance (%)
-18.03%
Price
24.05.24
€5.66
Summary
This prediction is currently active. The prediction for Biocryst Pharmaceuticals disappoints with a performance of -18.03%. This prediction currently runs until 04.08.24. The prediction end date can be changed by Jefferies_Financial_ at any time. Jefferies_Financial_ has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m |
---|---|---|
Biocryst Pharmaceuticals | -2.179% | -2.179% |
iShares Core DAX® | -0.205% | 2.528% |
iShares Nasdaq 100 | 1.613% | 4.733% |
iShares Nikkei 225® | -0.740% | 0.396% |
iShares S&P 500 | 0.267% | 2.720% |
Comments by Jefferies_Financial_ for this prediction
In the thread Biocryst Pharmaceuticals diskutieren
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) was upgraded by analysts at Jefferies Financial Group Inc. from a "hold" rating to a "buy" rating.
Ratings data for BCRX provided by MarketBeat